Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.49 |
| ▸ | MTOR | P42345 | 7/20 | 0.49 |
| ▸ | AKT1 | P31749 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919456 | 0.86 | PIK3CA (0.58) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2924265 | 0.85 | PIK3CA (0.52) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2930380 | 0.85 | PIK3CA (0.46) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2946540 | 0.75 | PIK3CA (0.49) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2925568 | 0.74 | PIK3CA (0.44) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2954923 | 0.73 | PIK3CA (0.45) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL3450911 | 0.73 | PIK3CA (0.46) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2926918 | 0.72 | PIK3CA (0.53) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| SCHEMBL2920507 | 0.72 | PIK3CA (0.51) | PIK3CAMTORAKT1PIK3CDPIK3CB | |
| Trifluoroacetic Acid SCHEMBL2927152 | 0.69 | PIK3CA (0.44) | PIK3CAMTORAKT1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | claimed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 28/4885AKT1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.